Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA:688266)

Market Cap	21.72B
Revenue (ttm)	533.91M
Net Income (ttm)	-136.22M
Shares Out	264.71M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,301,309
Average Volume	2,690,116
Open	82.75
Previous Close	83.16
Day's Range	80.65 - 85.49
52-Week Range	42.80 - 85.49
Beta	0.55
RSI	78.94
Earnings Date	Apr 19, 2025

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 867
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688266

Financial Performance

In 2024, SHA:688266's revenue was 533.91 million, an increase of 38.16% compared to the previous year's 386.44 million. Losses were -136.22 million, -51.10% less than in 2023.